Drug firm Alembic Pharmaceuticals today reported a consolidated net profit of Rs 93.79 crore for the quarter ended March 31, 2018.
The company had posted a net profit after taxes, non-controlling interests and share of profit/(loss) of associates and joint ventures of Rs 93.04 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in a filing to BSE.
Consolidated revenue from operations of the company stood at Rs 853.31 crore for the quarter under consideration. It was Rs 741.35 crore for the same period year ago.
For the fiscal year ended March this year, the company posted a net profit of Rs 412.63 crore as against Rs 403.16 crore for the year ago period.
Consolidated revenue from operations stood at Rs 3,130.81 crore for the fiscal year 2018. It was Rs 3,134.61 crore for the previous fiscal period.
The US generic business grew by 45 per cent during the quarter despite a challenging and dynamic business environment, Alembic Pharmaceuticals MD Pranav Amin said.
The company said its board has recommended a dividend of Rs 4 per equity share having face value of Rs 2 each.
Shares of Alembic Pharmaceuticals were today trading at Rs 476.55 per scrip in the afternoon trade on BSE, down 1.16 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)